Motif Bio PLC Potent Efficacy of Iclaprim Confirmed (8137W)

TIDMMTFB

RNS Number : 8137W

Motif Bio PLC

24 August 2015

Motif Bio plc

("Motif" or the "Company")

Potent Efficacy of Iclaprim Confirmed in Independent Laboratory Study

Motif (LSE: MTFB), the clinical stage biopharmaceutical company specialising in developing novel antibiotics, today announced the topline results of an independent report from microbiology specialists, JMI Laboratories. The report shows that iclaprim is effective in vitro against a range of Gram-positive bacteria, including Staphylococcus aureus, one of the key causes of acute bacterial skin and skin structure infection (ABSSSI) and hospital-acquired bacterial pneumonia (HABP).

The recently completed laboratory study tested iclaprim against more than 2,000 bacterial strains, including 1,178 strains of Staphylococcus aureus collected in 2014 from patients in the U.S.A., Europe, Asia Pacific, and Latin America. Iclaprim was found to be 16-fold more potent than trimethoprim, the only other antibacterial dihydrofolate reductase inhibitor (DHFRi) administered alone in today's market.

Reported minimum inhibitory concentrations (MICs) demonstrated that iclaprim is active against Staphylococcus aureus at very low concentrations. The MIC50, the minimum concentration of iclaprim required to kill 50% of tested bacteria, was 0.06 mcg/ml and the MIC90, the minimum concentration of iclaprim required to kill 90% of tested bacteria, was 0.12 mcg/ml. Comparing this to data for other antibiotics against the same 1,178 strains of Staphylococcus aureus, 1 mcg/ml of vancomycin and 1 mcg/ml of linezolid was required to meet the MIC50 and MIC90 levels. Against methicillin-resistant Staphylococcus aureus (MRSA), iclaprim was also highly active: the MIC50 was 0.06 mcg/ml and the MIC90 was 0.5 mcg/ml.

The tests were conducted according to Clinical and Laboratory Standards Institute (CLSI) methods. CLSI develops clinical laboratory testing standards based on input from and consensus among industry, government, and health care professionals around the world.

Dr. David Huang, Chief Medical Officer at Motif, commented: "These encouraging new results confirm the Board's confidence in developing iclaprim to treat ABSSSI and HABP. We believe that iclaprim will prove to be an important option for treating these life threatening infections where currently available treatments are not fully effective due to resistance or side effects."

Enquiries:

 
 Motif Bio plc.                          info@motifbio.com 
  Graham Lumsden (Chief Executive 
  Officer) 
  Robert Bertoldi (Chief Financial 
  Officer) 
  www.motifbio.com 
 
                                           +49 (0) 89 
 MC Services AG (TRADE PR)                 210 2280 
  Raimund Gabriel                          +44 (0) 207 
  Shaun Brown                              148 5998 
 Zeus Capital Partners Limited           +44 (0) 20 
  (BROKER and NOMAD)                      3709 0142 
 Phil Walker/ John Treacy 
  Dominic Wilson 
 Northland Capital Partners Limited      +44 (0) 20 
  (BROKER)                                7382 1100 
 Patrick Claridge/ David Hignell 
  John Howes/ Mark Treharne (Broking) 
 Plumtree Capital Limited (FINANCIAL     +44 (0) 207 
  ADVISOR)                                183 2493 
 Stephen Austin 
 Yellow Jersey PR Limited (FINANCIAL 
  PR) 
  Dominic Barretto 
  Philip Ranger                          +44 (0) 7768 
  Charles Goodwin                         537 739

Notes to Editors:

Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria.

Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.

The Company is in discussions with pharmaceutical companies and universities to build a pipeline of innovative antibiotics targeting Gram-positive and Gram-negative bacteria.

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCPJMFTMBMTBIA

(END) Dow Jones Newswires

August 24, 2015 02:00 ET (06:00 GMT)

Grafico Azioni Motif Bio (LSE:MTFB)
Storico
Da Giu 2024 a Lug 2024